Journal: Clinical and Translational Medicine

Article Title: Evolution of aberrant brain‐wide spatiotemporal dynamics of resting‐state networks in a Huntington's disease mouse model

doi: 10.1002/ctm2.70055

Figure Lengend Snippet: mHTT deposition in total cells and pericytes in zQ175DN mice across ages. (A) Immunofluorescence representative image for mHTT (2B4, white), pericytes (CD13, magenta) aligning blood vessels (lectin, green) and nuclei (DAPI, blue) in WT and zQ175DN HET in the lCPu at 6 months of age; between‐group comparison of (B) 2B4 coverage in all cells based on 2B4 spot total area relative to the cell area and (C) number of CD13+ cells across ages (mean ± SD, two‐way ANOVA, FDR, p < 0.05); (D) deposition of 2B4 in CD13+ cells in zQ175DN HET mice across regions at 3, 6, 8 and 12 months of age (mean ± SD, two‐way ANOVA, p < 0.05); post hoc comparisons represented as differences to a specific region ( ↓ ), FDR corrected, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, # p ≤ 0.1; mCPu medial caudate putamen, lCPu lateral caudate putamen, PiriCtx piriform cortex, InsCtx insular cortex, MCtx 1 motor cortex 1, MCtx 2 motor cortex 2, S1Ctx somatosensory cortex 1, CgCtx cingulate cortex.

Article Snippet: Two stainings were performed where the following primary antibodies were applied in the first staining (1) 2B4 – marker for mHTT (1:200, Sigma Eldrich, Cat. # MAB5492) and CD13 – marker for pericytes (1:100, R&D Systems, Cat. # AF2335) diluted in PBS + 5% NDS and in the second staining (2) 2B4 (1:200, Sigma Eldrich, Cat. # MAB5492), GFAP – marker for reactive astrocytes (1:1000, Abcam, Cat. # ab4674) and VEGF (1:100, Thermo Fisher, Cat. # MA5‐32038) were diluted in 0.1% Triton X‐100 and 1% NDS in PBS and incubated overnight at RT.

Techniques: Immunofluorescence, Comparison

Journal: Cardiovascular diabetology

Article Title: The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.

doi: 10.1186/s12933-024-02174-6

Figure Lengend Snippet: Fig. 6 Effect of Empagliflozin on vascularization after stroke. Confocal images (A) showing the expression in the striatum of non-diabetic controls (non-T2D), diabetic mice (T2D-VH) and diabetic mice treated with Empagliflozin (T2D-E) after stroke of CD13 (red) and PDXL (blue) evaluating vessel density (B), pericyte density (C), pericyte coverage (D) and parenchymal pericyte density (E). White arrows indicate the pericytes that are not associated with the vessels. Data are presented as mean ± SD. Statistical significance was calculated using two-way ANOVA followed by Benjamini, Krieger and Yekutieli multiple comparisons test. Results were considered statistically significant if p < 0.05. *denotes a difference between non-T2D and T2D-VH, §denotes a difference between T2D-VH and T2D-E, #denotes a difference between contralateral and ipsilateral hemisphere within the same group. Scale bar = 50 μm. non-T2D n = 5, T2D-VH n = 5, T2D-E n = 6

Article Snippet: For NeuN staining, sections were incubated in primary antibody solution for 48 h. The following primary antibodies were used: mouse anti-NeuN, a neuronal marker (1:500, #MAB377, Millipore, RRID:AB_2298772); goat anti-Iba1, a marker for microglia (1:1000, Ab5076, Abcam, RRID:AB_2220422); anti-DCX (doublecortin), a marker for migrating neuroblasts (1:200, sc-271390, Santa Cruz Biotechnology, RRID:AB_10610966); antiKi67, a marker for cell proliferation (1:300, ab15580, Abcam, RRID:AB_443209); goat anti-PDXL, a marker for endothelial cells (1:200, #AF1658, R&D Systems, RRID:JLD0117051); rat anti-CD13, a marker for pericytes (1:200, #MCA2183, Biorad, RRID:152021); rabbit antiNG2, a marker for activated pericytes (1:200, #AB5320, Millipore, RRID:3517406); rabbit anti-albumin (1:200, ab19196, Abcam, RRID:GR3271594-14); rabbit antifibrinogen (1:400, ab27913, Abcam, RRID:GR28863-14).

Techniques: Expressing, IF-P